Xeris Biopharma Holdings, Inc. (XERS) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "XERS"
      ],
      "issuer_cik": "0001867096",
      "owner_cik": "0002031695",
      "accession_number": "0001867096-26-000085",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Xeris Biopharma Holdings, Inc.",
      "issuer_trading_symbol": "XERS",
      "owner_name": "McCulloch Kevin",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 15000,
      "transaction_price_per_share": 9.408,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1599208,
      "transaction_value": 141120,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025."
        },
        {
          "id": "F2",
          "description": "The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
        }
      ],
      "remarks": "President and Chief Operating Officer"
    },
    {
      "tickers": [
        "XERS"
      ],
      "issuer_cik": "0001867096",
      "owner_cik": "0001652410",
      "accession_number": "0001867096-26-000084",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Xeris Biopharma Holdings, Inc.",
      "issuer_trading_symbol": "XERS",
      "owner_name": "Hecht Beth",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 16666,
      "transaction_price_per_share": 9.4079,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1111130,
      "transaction_value": 156792.0614,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025."
        },
        {
          "id": "F2",
          "description": "The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
        }
      ],
      "remarks": "Chief Legal Officer and Corporate Secretary"
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.